Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Investors

Fresenius Investment Highlights

Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management

"Particularly during the COVID-19 pandemic, Fresenius continues to make many important contributions to the provision of high-quality, affordable healthcare. In this way, we are standing with our patients around the world – and fulfilling our social responsibility. (…) Even with all the current uncertainties, we expect increasingly dynamic earnings development in the coming quarters. I therefore remain confident that 2020 will be another successful year for Fresenius."

(Stephan Sturm, Chairman of the Management Board)

LATEST

July 30, 2020 - 01:30 PM | Bad Homburg, Germany

Conference Call Q2 2020, Fresenius

Live Webcast

Webcast Import (ICS) Investor News (PDF) Presentation (PDF) Podcast (MP3) Transcript (PDF)

LATEST

News

Solid H1 results in light of significant contributions to combat COVID-19 – Accelerated earnings growth expected in H2 – New FY/20 guidance incorporates estimated COVID-19 effects

Fresenius Medical Care with very strong earnings growth and exceptional cash flow development in Q2; Fresenius Kabi impacted by fewer elective procedures and easing extra demand for COVID 19 related products in Europe and the U.S.; only gradual recovery in China; Fresenius Helios seeing gradual return of elective ...
July 30, 2020Fresenius
Brief News
Curalie cooperates with ‘Wir für Gesundheit‘ and Debeka

The Berlin-based digital health company Curalie, a subsidiary of the Fresenius healthcare group, has entered a cooperation agreement with the “Wir für Gesundheit” quality medical care network and the health insurer Debeka. In the first step, a prevention app through which regular medical check-ups can be carried out, along with other functions, will be added to PlusCard. A supplementary company health insurance that companies can offer to their employees, PlusCard was jointly developed by “Wir für Gesundheit” and Debeka and has been offered since 2014. Additional digital components are planned for the prevention app, including a telemedicine function for the care of chronically ill patients.

July 28, 2020Fresenius

Brief News
Fresenius Helios publishes sustainability report

Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals, the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

July 08, 2020Fresenius Helios
Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged

July 08, 2020Fresenius

Brief News
Fresenius Kabi expands pre-filled syringe portfolio in the U.S.

Morphine Sulfate Injection is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes in MicroVault packaging. MicroVault packaging is designed to support the secure dispensing of controlled substances, for example via transparent hard plastic packaging allowing bar code scanning and visual inspection as well as a tamper evident seal.

June 23, 2020Fresenius Kabi
Brief News
Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

June 15, 2020Fresenius Kabi

Fresenius Helios acquires hospital in western Germany

May 29, 2020Fresenius Helios
Brief News
Fresenius Kabi enters marketing agreement for biosimilar product

Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

May 28, 2020Fresenius Kabi

Brief News
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by FDA

Fresenius Kabi announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company`s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is an important achievement in the development of Fresenius Kabi’s biosimilar pipeline in the US. Fresenius Kabi also received acceptance for review of its regulatory submission for its pegfilgrastim biosimilar candidate from the European Medicines Agency this month. (* Neulasta® is a registered trademark of Amgen)

May 27, 2020Fresenius Kabi
Brief News
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA

The European Medicines Agency (EMA) has accepted for review Fresenius Kabi`s Marketing Authorization Application (MAA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is another milestone for Fresenius Kabi following last year`s approval and launch of the company`s adalimumab biosimilar (Idacio®) in Europe. (* Neulasta® is a registered trademark of Amgen)

May 22, 2020Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Micafungin for injection, an antifungal medicine, expands the company's anti-infective portfolio.

May 12, 2020Fresenius Kabi
Brief News
Fresenius Kabi introduces new presentations of Potassium Phosphates Injection

Potassium Phosphates Injection is now available in the United States in three FDA-approved presentations. Fresenius Kabi offers the broadest portfolio of Potassium Phosphates Injection in the United States.

May 07, 2020Fresenius Kabi

Solid start to 2020 – Fresenius proves its resilience in light of significant COVID-19 effects

May 06, 2020Fresenius
Brief News
Fresenius Helios develops process for safe reuse of masks

Fresenius Helios has developed a secure and highly effective process for purifying medical protective masks so they can be safely reused. It is being employed for FFP2- and FFP3-type masks, which help protect medical and care personnel who are treating COVID-19 patients. Going well beyond the safety standard set out by the Robert Koch Institute, Germany’s government agency responsible for disease control and prevention, the process allows the purified masks to be used by any staff member – not just the previous user. Starting immediately, Helios Germany’s hospitals can purify 8,000 masks daily using the process, which was developed with the support of Fresenius Vamed and Fresenius Medical Care. The company has chosen not to commercialize the process and is making complete information about it available online, free of charge.

April 22, 2020Fresenius Helios

Brief News
Fresenius Helios supports COVID-19 research

To obtain and secure important data for research into SARS-CoV 2, Fresenius Helios has established a multi-center COVID-19 register. Since back in February a team of Helios experts, supported by the Brandenburg Medical School outside of Berlin, has been gathering pseudonymized data on patients treated for COVID-19 in Germany. The goal is to develop insights and knowledge for the battle against the new virus. First research findings from the project, which is scheduled to last a year and is financed by Helios, are now being readied for publication.

April 20, 2020Fresenius Helios
Fresenius Kabi takes comprehensive measures to increase supply of essential drugs during COVID 19 pandemic

April 07, 2020Fresenius Kabi

Fresenius successfully places bonds with a volume of 750 million euros

March 31, 2020Fresenius
Fresenius postpones 2020 Annual General Meeting

March 30, 2020Fresenius

Fresenius takes comprehensive measures to combat COVID 19 pandemic in Germany

March 27, 2020Fresenius Helios
Brief News
Fresenius Kabi resumes normal operations in China

With virtually all of Fresenius Kabi’s manufacturing staff in China returning to work post government-imposed COVID-19 quarantine restrictions, the company is ramping-up production back to normal levels. With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China. Even though Fresenius Kabi faced challenges due to the COVID-19 pandemic and the quarantine measures, there was no major interruption of production. Thus, the company can supply the Chinese population with essential pharmaceuticals and medical devices.

March 24, 2020Fresenius Kabi

Fresenius Helios makes significant contribution to combating COVID-19 crisis in Spain

March 20, 2020Fresenius Helios
Brief News
Fresenius annual report 2019 online available

Our Annual Report 2019 is now available as a full-content PDF download and as an online short-version with the highlights. Annual Report (PDF) Online short-version

March 18, 2020Fresenius

Brief News
Fresenius subsidiary Curalie acquires Digitale Gesundheitsgruppe

Curalie, a subsidiary of Fresenius, has acquired Digitale Gesundheitsgruppe (DGG), one of its main competitors in Germany. Curalie and DGG both develop digital healthcare offerings to help patients with chronic illnesses. DGG targets family and specialist physicians with its “TeLiPro” telemedicine platform, while Curalie develops digital solutions for rehabilitation and aftercare. Combining the two companies creates the first provider that in all sectors of healthcare can digitally support patients during outpatient and inpatient care and through to aftercare.

March 18, 2020Fresenius
Brief News
Fresenius Kabi launches IV solution in the U.S.

Sodium Chloride 3% is the newest addition to the company’s IV solution portfolio.

March 16, 2020Fresenius Kabi

Fresenius reports 16th consecutive record year - Significant investments into growth – Healthy growth for 2020 expected – Medium-term growth targets confirmed

February 20, 2020Fresenius
Brief News
Fresenius Kabi and Vifor Pharma create joint venture in China for i.v. iron portfolio

Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.

February 20, 2020Fresenius Kabi

Fresenius Helios acquires first hospital in Bogotá, continuing expansion in Colombia’s private hospital market

February 19, 2020Fresenius Helios
Brief News
Fresenius Kabi diversifies U.S. product portfolio

With the launch of a Glucagon Emergency Kit, Fresenius Kabi offers an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes. This is the company’s first pharma product sold and used primarily outside hospitals in the U.S.

February 05, 2020Fresenius Kabi

Brief News
Fresenius Kabi enters into joint venture to advance new cell and gene therapies

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No other financial terms were disclosed.

January 21, 2020Fresenius Kabi
Brief News
Fresenius Helios trains doctors in antibiotics management

Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

January 16, 2020Fresenius Helios

Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

I am a private investor I am an institutional investor

Title *

First name * Please enter your first name.

Last name * Please enter your last name.

Company * Please enter your company.

Department * Please enter your department.

Job function *

Please enter your function.

Street / Number * Please enter your street.

Postal Code / City * Please enter your postal code and city.

Country *

E-mail * Please enter your e-mail address.

Telephone number

All fields marked with * are required.

Please send me via email

Fresenius Brief News German English

Fresenius Investor News German English

Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us